Single‐cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer

Single‐cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer

Saved in:

Bibliographic Details
Main Authors:	Shiyun Chen, Zhaoli Tan, Xiaojie Wu, Yanli Lin, Xiang Li, Yumeng Cui, Weiling Man, Fang Pang, Yanghua Li, Faliang Shi, Lu Han, Miaomiao Gou, Li Zhou, Zhikuan Wang, Youliang Wang, Guanghai Dai
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Clinical and Translational Medicine
Online Access:	https://doi.org/10.1002/ctm2.70151
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-05-01)

A New Chapter in Colorectal Cancer Treatment: Insights from 2024 ASCO Annual Meeting
by: Miaomiao GOU, et al.
Published: (2024-12-01)

Plasmolipin deficiency is essential for HUVECs survival under hypoxic conditions
by: Yanghua Li, et al.
Published: (2025-05-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer
by: Guang Yang, et al.
Published: (2025-06-01)

Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
by: Miaomiao Gou, et al.
Published: (2021-01-01)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
by: Roberto Benelli, et al.
Published: (2022-12-01)

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
by: Zheng Jiang, et al.
Published: (2013-01-01)

MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3
by: Chun Peng, et al.
Published: (2024-12-01)

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy
by: Nan Zhang, et al.
Published: (2025-02-01)

Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges
by: Bo Pei PhD, et al.
Published: (2025-05-01)

[Comment] Compara tive effectiveness of bevacizumab versus cetuximab in meta static colorectal cancer patients without primary tumor resec tion
by: Li Yingru, et al.
Published: (2022-08-01)

Case Report: A case of interstitial pneumonia in a colorectal cancer patient with a history of lung cancer treated with cetuximab
by: Yang Yang, et al.
Published: (2025-07-01)

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
by: Anita K Gandhi, et al.
Published: (2013-01-01)

Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
by: Anita Ramesh
Published: (2025-07-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

[Comment] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): a randomized controlled trial
by: Zhang Rongxin
Published: (2024-08-01)

Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
by: Kumar Prabhash, et al.
Published: (2025-07-01)

Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia
by: Gihan Elsisi, et al.
Published: (2025-03-01)

Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer
by: Huanrong Ma PhD, et al.
Published: (2021-09-01)

Surveillance and Surgical Salvage Treatment for Endoscopically Removed T1 Colorectal Cancers
by: Hiroyuki Takamaru, et al.
Published: (2025-07-01)

Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis
by: Sukesh Manthri, et al.
Published: (2017-01-01)

Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement
by: Carmen Navarrete‐Sirvent, et al.
Published: (2025-06-01)

The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis
by: Marryam Azeem, et al.
Published: (2025-02-01)

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
by: Jiefu Zhou, et al.
Published: (2025-03-01)

N6-methyladenosine modification of MEF2A weakens cetuximab sensitivity in colorectal cancer via PD-L1/SOX12 axis
by: Cao Gao, et al.
Published: (2025-07-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Cetuximab and Paclitaxel Drug Response in Head and Neck Tumor Stem Cells
by: Vilson Serafim Júnior, et al.
Published: (2025-02-01)

Salvage treatment of a metastatic colorectal cancer with pMMR/MSS in a 21-year-old man: a case report
by: Xuesong Li, et al.
Published: (2025-08-01)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
by: Weiyi Qiu, et al.
Published: (2019-01-01)

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
by: Xuefeng Wang, et al.
Published: (2025-03-01)

Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs
by: W. Lv, et al.
Published: (2017-01-01)

Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study
by: A. Fernández-Montes, et al.
Published: (2024-09-01)

Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
by: Jianxin Chen, et al.
Published: (2025-02-01)

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
by: Yuankai Shi, et al.
Published: (2025-05-01)

Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy
by: Yue Ma, et al.
Published: (2024-12-01)

Limb salvage surgery
by: Dinesh Kadam
Published: (2013-01-01)

Exploring potential therapeutic targets for colorectal tumors based on whole genome sequencing of colorectal tumors and paracancerous tissues
by: Yufan Sheng, et al.
Published: (2025-07-01)